Immix Biopharma Inc (IMMX) Stock Analysis

Immix Biopharma Inc (IMMX) is a publicly traded company in the HEALTHCARE sector. It trades at $8.37, carries a market capitalization of $640.71M. This page summarizes the public market data, fundamentals, and frequently asked questions for IMMX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Immix Biopharma Inc currently has a Neutral sentiment score of 0.12.

About Immix Biopharma Inc

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Los Angeles, California, dedicated to developing innovative tissue-specific therapies targeting oncology and inflammatory diseases. The company is advancing a strong pipeline of drug candidates aimed at fulfilling significant unmet medical needs in both the United States and Australia. Through its commitment to cutting-edge research and strategic collaborations, Immix is establishing itself as a key player in...

GNG Research Analysis

GNG Research scores Immix Biopharma Inc (IMMX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for IMMX.

Frequently Asked Questions

Does IMMX pay dividends?

Immix Biopharma Inc (IMMX) does not currently pay a regular dividend.

What is IMMX's market cap?

Immix Biopharma Inc (IMMX) has a market capitalization of $640.71M with a current stock price of $8.37.